144 related articles for article (PubMed ID: 25263078)
21. Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma.
Aide N; Talbot M; Fruchart C; Damaj G; Lasnon C
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):699-711. PubMed ID: 29214417
[TBL] [Abstract][Full Text] [Related]
22. [Utility and prognostic value of PET/CT, bone marrow biopsy and aspirate for detection of bone marrow involvement in diffuse large B-cell lymphoma].
Jiang XY; Zou DM; Zhang YQ; Wang Z; Zhang W; Zhou DB; Zhang Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):663-667. PubMed ID: 36709151
[No Abstract] [Full Text] [Related]
23. Biopsy remains indispensable for evaluating bone marrow involvement in DLBCL patients despite the use of positron emission tomography.
Saiki Y; Tomita N; Uchida A; Uemura Y; Suzuki Y; Hirakawa T; Kato M; Hoshikawa M; Kawano T; Nakamura N; Miura I; Arai A
Int J Hematol; 2021 May; 113(5):675-681. PubMed ID: 33515158
[TBL] [Abstract][Full Text] [Related]
24. Bone marrow FDG-PET/CT in Hodgkin lymphoma revisited: do imaging and pathology match?
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Ann Nucl Med; 2015 Feb; 29(2):132-7. PubMed ID: 25348549
[TBL] [Abstract][Full Text] [Related]
25. Bone marrow biopsy can be omitted in the diagnostic workup of CNS lymphoma of DLBCL origin: a population-based retrospective study in the PET-CT era.
Jelicic J; Hansen DL; Carlsen SS; Thorsgaard M; Hersby DS; Kannik K; Munksgaard ASE; Larsen TS; Juul-Jensen K
Ann Hematol; 2023 Jul; 102(7):1897-1905. PubMed ID: 37246974
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of bone marrow infiltration detected by PET-CT in newly diagnosed diffuse large B cell lymphoma.
Liang JH; Sun J; Wang L; Fan L; Chen YY; Qu XY; Li TN; Li JY; Xu W
Oncotarget; 2016 Apr; 7(14):19072-80. PubMed ID: 26919239
[TBL] [Abstract][Full Text] [Related]
27. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
[TBL] [Abstract][Full Text] [Related]
28. Role of bone marrow biopsy in staging of patients with classical Hodgkin's lymphoma undergoing positron emission tomography/computed tomography.
Puccini B; Nassi L; Minoia C; Volpetti S; Ciancia R; Riccomagno PC; Di Rocco A; Mulè A; Toldo C; Sassone MC; Guariglia R; Filì C; Finolezzi E; Falorio S; Zanon S; Furlan A; Doa G; Zaja F;
Ann Hematol; 2017 Jul; 96(7):1147-1153. PubMed ID: 28451805
[TBL] [Abstract][Full Text] [Related]
29. [Diagnostic and prognostic values of flow cytometry in diffuse large B-cell lymphoma with bone marrow involvement].
Hong Y; Wan WL; Li M; Wang H; Dong F; Jing HM; Ke XY; Zhu MX
Zhonghua Yi Xue Za Zhi; 2023 Aug; 103(29):2258-2265. PubMed ID: 37544763
[No Abstract] [Full Text] [Related]
30. Performance of Positron Emission Tomography-Computed Tomography and Bone Marrow Biopsy in Detecting Bone Marrow Infiltration in Lymphoma Cases.
Büyükşimşek M; Kolsuz İ; Yetişir AE; Tohumcuoğlu M; Oğul A; Mirili C; Paydaş S; Güney İB
Turk J Haematol; 2020 Nov; 37(4):220-225. PubMed ID: 32003552
[TBL] [Abstract][Full Text] [Related]
31. Potential prognostic implications of whole-body bone marrow MRI in diffuse large B-cell lymphoma patients with a negative blind bone marrow biopsy.
Adams HJ; Kwee TC; Lokhorst HM; Westerweel PE; Fijnheer R; Kersten MJ; Verkooijen HM; Stoker J; Nievelstein RA
J Magn Reson Imaging; 2014 Jun; 39(6):1394-400. PubMed ID: 24310955
[TBL] [Abstract][Full Text] [Related]
32. Can FDG-PET/CT replace blind bone marrow biopsy of the posterior iliac crest in Ewing sarcoma?
Kasalak Ö; Glaudemans AWJM; Overbosch J; Jutte PC; Kwee TC
Skeletal Radiol; 2018 Mar; 47(3):363-367. PubMed ID: 29124298
[TBL] [Abstract][Full Text] [Related]
33. Loss of utility of bone marrow biopsy as a staging evaluation for Hodgkin lymphoma in the positron emission tomography-computed tomography era: a West of Scotland study.
Hamilton R; Andrews I; McKay P; Leach M
Leuk Lymphoma; 2014 May; 55(5):1049-52. PubMed ID: 23915196
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the prognostic utility of bone marrow biopsy in diffuse large B-Cell lymphoma in the SEER-Medicare dataset.
Luan D; Wu Y; Goldstein J; Rutherford S; Leonard JP; Martin P
Leuk Lymphoma; 2021 Aug; 62(8):1850-1859. PubMed ID: 33627025
[TBL] [Abstract][Full Text] [Related]
35. Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma.
St-Pierre F; Broski SM; LaPlant BR; Maurer MJ; Ristow K; Thanarajasingam G; Macon WR; Habermann TM; Witzig TE
Oncologist; 2020 Aug; 25(8):689-695. PubMed ID: 32319706
[TBL] [Abstract][Full Text] [Related]
36. Early risk stratification for diffuse large B-cell lymphoma integrating interim Deauville score and International Prognostic Index.
Yim SK; Yhim HY; Han YH; Jeon SY; Lee NR; Song EK; Jeong HJ; Kim HS; Kwak JY
Ann Hematol; 2019 Dec; 98(12):2739-2748. PubMed ID: 31712879
[TBL] [Abstract][Full Text] [Related]
37. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
[TBL] [Abstract][Full Text] [Related]
38. PET/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in part of patients newly diagnosed with extranodal natural killer/T-cell lymphoma.
Wang Y; Xie L; Tian R; Deng Y; Zhang W; Zou L; Zhang H; Liu J; Zhao S; Ding W; Liu W; Jiang M
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2529-2539. PubMed ID: 31485768
[TBL] [Abstract][Full Text] [Related]
39. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
Buchmann I; Reinhardt M; Elsner K; Bunjes D; Altehoefer C; Finke J; Moser E; Glatting G; Kotzerke J; Guhlmann CA; Schirrmeister H; Reske SN
Cancer; 2001 Mar; 91(5):889-99. PubMed ID: 11251940
[TBL] [Abstract][Full Text] [Related]
40. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β
Montalbán C; Díaz-López A; Dlouhy I; Rovira J; Lopez-Guillermo A; Alonso S; Martín A; Sancho JM; García O; Sánchez JM; Rodríguez M; Novelli S; Salar A; Gutiérrez A; Rodríguez-Salazar MJ; Bastos M; Domínguez JF; Fernández R; Gonzalez de Villambrosia S; Queizan JA; Córdoba R; de Oña R; López-Hernandez A; Freue JM; Garrote H; López L; Martin-Moreno AM; Rodriguez J; Abraira V; García JF;
Br J Haematol; 2017 Mar; 176(6):918-928. PubMed ID: 28106247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
